These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


236 related items for PubMed ID: 24841356

  • 1. Current trends in the management of malignant peritoneal mesothelioma.
    Miura JT, Johnston FM, Gamblin TC, Turaga KK.
    Ann Surg Oncol; 2014 Nov; 21(12):3947-53. PubMed ID: 24841356
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Repeat cytoreductive surgery and heated intraperitoneal chemotherapy may offer survival benefit for intraperitoneal mesothelioma: a single institution experience.
    Wong J, Koch AL, Deneve JL, Fulp W, Tanvetyanon T, Dessureault S.
    Ann Surg Oncol; 2014 May; 21(5):1480-6. PubMed ID: 24158467
    [Abstract] [Full Text] [Related]

  • 4. Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis.
    Magge D, Zenati MS, Austin F, Mavanur A, Sathaiah M, Ramalingam L, Jones H, Zureikat AH, Holtzman M, Ahrendt S, Pingpank J, Zeh HJ, Bartlett DL, Choudry HA.
    Ann Surg Oncol; 2014 Apr; 21(4):1159-65. PubMed ID: 24322529
    [Abstract] [Full Text] [Related]

  • 5. Institutional learning curve of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for peritoneal malignancies.
    Polanco PM, Ding Y, Knox JM, Ramalingam L, Jones H, Hogg ME, Zureikat AH, Holtzman MP, Pingpank J, Ahrendt S, Zeh HJ, Bartlett DL, Choudry HA.
    Ann Surg Oncol; 2015 May; 22(5):1673-9. PubMed ID: 25377640
    [Abstract] [Full Text] [Related]

  • 6. Preoperative Thrombocytosis Predicts Shortened Survival in Patients with Malignant Peritoneal Mesothelioma Undergoing Operative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy.
    Li YC, Khashab T, Terhune J, Eckert RL, Hanna N, Burke A, Richard Alexander H.
    Ann Surg Oncol; 2017 Aug; 24(8):2259-2265. PubMed ID: 28324285
    [Abstract] [Full Text] [Related]

  • 7. Malignant Peritoneal Mesothelioma: Patterns of Care and Survival in the Netherlands: A Population-Based Study.
    de Boer NL, van Kooten JP, Damhuis RAM, Aerts JGJV, Verhoef C, Madsen EVE.
    Ann Surg Oncol; 2019 Dec; 26(13):4222-4228. PubMed ID: 31620941
    [Abstract] [Full Text] [Related]

  • 8. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome.
    Ihemelandu C, Bijelic L, Sugarbaker PH.
    Ann Surg Oncol; 2015 May; 22(5):1680-5. PubMed ID: 25120250
    [Abstract] [Full Text] [Related]

  • 9. The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
    Kusamura S, Torres Mesa PA, Cabras A, Baratti D, Deraco M.
    Ann Surg Oncol; 2016 May; 23(5):1468-73. PubMed ID: 26572754
    [Abstract] [Full Text] [Related]

  • 10. Recurrence of Optimally Treated Malignant Peritoneal Mesothelioma with Cytoreduction and Heated Intraperitoneal Chemotherapy.
    Heller DR, Chiuzan C, Taub RN, Leinwand JC, Greene AM, Bates GE, Chabot JA, Kluger MD.
    Ann Surg Oncol; 2017 Dec; 24(13):3818-3824. PubMed ID: 29027138
    [Abstract] [Full Text] [Related]

  • 11. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis.
    Helm JH, Miura JT, Glenn JA, Marcus RK, Larrieux G, Jayakrishnan TT, Donahue AE, Gamblin TC, Turaga KK, Johnston FM.
    Ann Surg Oncol; 2015 May; 22(5):1686-93. PubMed ID: 25124472
    [Abstract] [Full Text] [Related]

  • 12. Conversion to Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma After Bidirectional Chemotherapy.
    Le Roy F, Gelli M, Hollebecque A, Honoré C, Boige V, Dartigues P, Benhaim L, Malka D, Ducreux M, Elias D, Goéré D.
    Ann Surg Oncol; 2017 Nov; 24(12):3640-3646. PubMed ID: 28849389
    [Abstract] [Full Text] [Related]

  • 13. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma: mitomycin versus cisplatin.
    Blackham AU, Shen P, Stewart JH, Russell GB, Levine EA.
    Ann Surg Oncol; 2010 Oct; 17(10):2720-7. PubMed ID: 20422458
    [Abstract] [Full Text] [Related]

  • 14. Long-term survival outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy: Single-institutional experience with 1225 cases.
    Kyang LS, Alzahrani NA, Valle SJ, Rahman MK, Arrowaili A, Liauw W, Morris DL.
    J Surg Oncol; 2019 Sep; 120(4):794-802. PubMed ID: 31309588
    [Abstract] [Full Text] [Related]

  • 15. Malignant peritoneal mesothelioma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is GLUT1 expression a major prognostic factor? A preliminary study.
    Hommell-Fontaine J, Isaac S, Passot G, Decullier E, Traverse-Glehen A, Cotte E, You B, Mohamed F, Gilly FN, Glehen O, Berger F.
    Ann Surg Oncol; 2013 Nov; 20(12):3892-8. PubMed ID: 23800898
    [Abstract] [Full Text] [Related]

  • 16. Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.
    de Boer NL, van Kooten JP, Burger JWA, Verhoef C, Aerts JGJV, Madsen EVE.
    BMJ Open; 2019 May 14; 9(5):e026779. PubMed ID: 31092657
    [Abstract] [Full Text] [Related]

  • 17. Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study.
    Kepenekian V, Elias D, Passot G, Mery E, Goere D, Delroeux D, Quenet F, Ferron G, Pezet D, Guilloit JM, Meeus P, Pocard M, Bereder JM, Abboud K, Arvieux C, Brigand C, Marchal F, Classe JM, Lorimier G, De Chaisemartin C, Guyon F, Mariani P, Ortega-Deballon P, Isaac S, Maurice C, Gilly FN, Glehen O, French Network for Rare Peritoneal Malignancies (RENAPE).
    Eur J Cancer; 2016 Sep 14; 65():69-79. PubMed ID: 27472649
    [Abstract] [Full Text] [Related]

  • 18. Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study.
    Malgras B, Gayat E, Aoun O, Lo Dico R, Eveno C, Pautrat K, Delhorme JB, Passot G, Marchal F, Sgarbura O, Ferron G, Goéré D, Andre T, Pocard M, RENAPE Network.
    Ann Surg Oncol; 2018 Oct 14; 25(11):3271-3279. PubMed ID: 29978366
    [Abstract] [Full Text] [Related]

  • 19. Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales.
    Linton A, Pavlakis N, O'Connell R, Soeberg M, Kao S, Clarke S, Vardy J, van Zandwijk N.
    Br J Cancer; 2014 Oct 28; 111(9):1860-9. PubMed ID: 25188323
    [Abstract] [Full Text] [Related]

  • 20. Treating peritoneal mesothelioma with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. A case series and review of the literature.
    Stamou K, Tsamis D, Pallas N, Samanta E, Courcoutsakis N, Prassopoulos P, Tentes AA.
    Int J Hyperthermia; 2015 Oct 28; 31(8):850-6. PubMed ID: 26382910
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 12.